New York State Teachers Retirement System Cuts Stock Holdings in BioLife Solutions, Inc. (NASDAQ:BLFS)

New York State Teachers Retirement System lowered its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 3.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 60,476 shares of the medical equipment provider’s stock after selling 1,900 shares during the quarter. New York State Teachers Retirement System owned 0.13% of BioLife Solutions worth $1,570,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. State Street Corp grew its stake in BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Geode Capital Management LLC grew its stake in BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after purchasing an additional 18,473 shares during the last quarter. Rockefeller Capital Management L.P. increased its stake in shares of BioLife Solutions by 81.3% in the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock worth $14,661,000 after acquiring an additional 262,504 shares during the period. Stephens Investment Management Group LLC boosted its position in BioLife Solutions by 16.7% in the 4th quarter. Stephens Investment Management Group LLC now owns 495,970 shares of the medical equipment provider’s stock worth $12,875,000 after purchasing an additional 70,875 shares in the last quarter. Finally, Curi RMB Capital LLC boosted its holdings in BioLife Solutions by 0.5% during the third quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock worth $10,565,000 after buying an additional 2,283 shares in the last quarter. 93.24% of the stock is owned by institutional investors.

BioLife Solutions Trading Down 3.1 %

Shares of BLFS opened at $26.67 on Friday. The firm has a market capitalization of $1.24 billion, a P/E ratio of -25.16 and a beta of 1.91. BioLife Solutions, Inc. has a twelve month low of $14.50 and a twelve month high of $29.55. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The stock’s fifty day simple moving average is $26.93 and its 200 day simple moving average is $25.49.

Insider Buying and Selling

In other news, CFO Troy Wichterman sold 987 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the sale, the chief financial officer now directly owns 121,779 shares of the company’s stock, valued at $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Aby J. Mathew sold 7,604 shares of BioLife Solutions stock in a transaction on Monday, December 16th. The shares were sold at an average price of $27.33, for a total transaction of $207,817.32. Following the completion of the sale, the executive vice president now directly owns 276,315 shares of the company’s stock, valued at approximately $7,551,688.95. The trade was a 2.68 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,678 shares of company stock worth $317,990. Insiders own 2.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BLFS. Northland Securities raised their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. TD Cowen boosted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Benchmark reissued a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. HC Wainwright decreased their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Finally, Craig Hallum upped their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, BioLife Solutions has a consensus rating of “Moderate Buy” and a consensus price target of $29.43.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.